Reuters logo
Bayer submits cancer drug for market authorisation in Japan
December 21, 2012 / 7:11 AM / 5 years ago

Bayer submits cancer drug for market authorisation in Japan

FRANKFURT, Dec 21 (Reuters) - Germany’s Bayer has submitted its cancer drug regorafenib, used for the treatment of gastrointestinal stromal tumors, for market authorisation in Japan, it said on Friday. (Reporting by Christoph Steitz)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below